What is Phoska Biopharma?
Phoska Biopharma is a preclinical stage company developing treatments targeting the peroxisome metabolism. They are lean and experienced team 100% focused on preclinical execution program to deliver PoC for its lead candidate within 6 months and an IND package within 24 months.
Recent data have shown the key role of peroxisome metabolism in multiple orphan diseases as well as in large neurodegenerative conditions.
PeroxiScanTM: proprietary screening platform leveraging our two-prong candidate screening approach:
- Peroxisome metabolism engagement: large patient datasets to validate the mechanism of action and specificity of our targets in areas of true unmet clinical need
- Neurological tissue exposure through a MFSD2A transporter engagement: ensuring a targeted mechanism of action
Within 3 month of formation: Phoska has assembled a world class pharma execution team with lipidomic experts, medicinal chemists, synthetic chemists, lipid biology experts, pre-clinical team and a pharmaceutical IP team.